AMAALA
AMAALA, the ultra-luxury destination located along Saudi Arabia’s north western coast, took to the seas with Monaco-based OceanoScientific on a two-week scientific expedition. The expedition was in line with AMAALA’s desire to measure and understand the impact of river water pollutants on human and sea life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201104005308/en/
The expedition was undertaken with a two-fold objective to determine the nature and density of the chemical compounds that affect the marine environment. It also placed a wider focus on the impact of chemical contaminants on the ocean and human health, and validates the applicability of the expedition’s sampling method, using a cost-effective research alternative with a zero-carbon emission vessel.
Over the course of two weeks, the crew collected water samples from various points within a triangle of 1,500 nautical miles in the western Mediterranean.
These samples were handed over to the Institut Français de Recherche pour l'Exploitation de la Mer (Ifremer) by the crew and AMAALA Chief Executive Officer Nicholas Naples and Chief Sustainability Officer Brendan Jack at the last port of call in La Seyne-sur-Mer, France. The scientists at the Ifremer, who advised on the scientific aspects of the undertaking, will now quantify and analyse the concentration of metals and elements such as cadmium, lead, nickel and mercury, all of which can alter the composition of the sea and affect the marine food chain.
The expedition and the results unearthed as part of its study will inform AMAALA’s own conservation efforts. The Red Sea and the Mediterranean Sea are neighbouring seas and part of one global ocean system where changes in one, create ripples in the other. With its vibrant coral gardens and rich underwater life, the Red Sea coast at AMAALA has a thriving ecosystem that the destination aims to preserve and nurture. To this end, it has forged partnerships with global marine conservation entities, including the Prince Albert II of Monaco Foundation, the Centre Scientifique de Monaco, and the Oceanographic Institute.
Commenting on the expedition, AMAALA Chief Executive Officer Nicholas Naples, said “We are proud to sponsor the OceanoScientific Expedition – it perfectly aligns with our goal to create a luxury destination that is a global leader in sustainable tourism. Being part of expeditions and studies like this, arms us with the deeper insight and scientific knowledge required to preserve and protect our local ecosystem, especially the Red Sea coral reefs. This expedition also illustrates our vision of creating experiences that brings diverse interests and cultures together.”
Yvan Griboval, circumnavigator explorer and member of the Yacht Club de Monaco, who led the expedition said, “While almost everyone has realised that plastic pollution is an appalling scourge on the ocean, we want to show that chemical contaminants - metallic and organic - that pollute the sea and poison the phytoplankton and plankton at the start of the food chain, are found in our dinner plates at the other end of the chain of life.”
The expedition was conducted on the specially commissioned AMAALA Explorer, a former record-breaking 110-foot racing maxi-catamaran that was converted into a scientific research ship with zero carbon emissions. It functioned as the expedition’s lodging and lab.
HSH Prince Albert II of Monaco on 15 October 2020 was on hand to bid the crew farewell from the marina of the Yacht Club de Monaco. The AMAALA Explorer made port calls in Porto Cervo, Italy; Barcelona, Spain; and La Seyne-sur-Mer, France where water samples were handed over to scientists, before returning to Monaco.
The vessel and expedition were skippered by Yvan Griboval, who worked with a team of scientists specialised in the study of organic contaminants, including an onboard Swedish marine scientist Linn Sekund and AMAALA Director of Sports Marc Archer.
A short documentary film about the expedition, in English and French, will be distributed in 2021, along with scientific results in late 2021 and scientific publication in late 2023.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201104005308/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom